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Abstract
Early in the age of modern medicine the consequences of vitamin A deficiency drew attention to
the fundamental link between retinoid-dependent homeostatic regulation and malignant
hyperproliferative diseases. The term retinoid includes a handful of endogenous and a large group
of synthetic derivatives of vitamin A. These multifunctional lipid-soluble compounds directly
regulate target genes of specific biological functions and critical signaling pathways to orchestrate
complex functions from vision to development, metabolism and inflammation. Many of the
retinoid activities on the cellular level have been well characterized and translated to the regulation
of processes like differentiation and cell death, which play critical roles in the outcome of
malignant transformation of tissues. In fact, retinoid-based differentiation therapy of acute
promyelocytic leukemia was one of the first successful examples of molecularly targeted treatment
strategies. The selectivity, high receptor binding affinity and the ability of retinoids to directly
modulate gene expression programs present a distinct pharmacological opportunity for cancer
treatment and prevention. However, to fully exploit their potential, the adverse effects of retinoids
must be averted. In this review we provide an overview of the biology of retinoid (activated by
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nuclear retinoic acid receptors, RARs) and rexinoid (engaged by nuclear retinoid X receptors,
RXRs) action concluded from a long line of preclinical studies, in relation to normal and
transformed states of cells. We will also discuss the past and current uses of retinoids in the
treatment of malignancies, the potential of rexinoids in the cancer prevention setting, both as
single agents and in combinations.
Introduction and historic background
The term ‘retinoid’ refers to all natural and synthetic compounds that have structural or
biological activities similar to retinol or vitamin A. Their versatile biological activities
include pattern formation during embryogenesis, vision, energy homeostasis, metabolism,
immune function and inflammation. The classical mechanism of retinoid action is a nuclear
hormone receptor-mediated activation of the transcriptional machinery acting on select
target genes. Counterintuitively, retinoid receptors exert extranuclear and non-transcriptional
effects as well, for instance by inducing rapid and transient activation of kinase cascades.
The sum of the transcriptional programs and non-genomic effects amount to a broad
spectrum of biological events regulated by retinoids. While the exact molecular mechanism
regulating complex processes may be elusive, the propensity to coordinately target multiple
pathways and regulatory mechanisms may account for their vast therapeutic potential.
Early rodent experiments using a retinoid deficient diet showed dysplastic alterations of
various epithelial tissues, and an inverse correlation has been established between serum
retinoid levels and extent of dedifferentiation or metaplasias. Aberrant retinoid signaling
mechanisms have been identified as causative factors of certain cancers, suggesting that
retinoid pathways may be suitable targets to treat certain forms of malignant diseases.
Therefore, the ability of retinoids to exert anticancer activity against epithelial tumors has
been in the forefront of interest since the 1950s [1, 2], with investigations later extending to
a variety of tissues [3]. At the same time it was proposed that retinoids might also be
effective as a neoplastic prophylactic intervention [4, 5]. One of the earliest clinical
observations in this area established that treatment with 13-cis-retinoic acid (13-cis-RA,
isotretinoin) would delay the development of second primary head and neck squamous cell
carcinomas, a major cause of mortality in patients after successful treatment of the primary
tumor [6]. 13-cis-RA has also been reported to cause clinical resolution of upper
aerodigestive tract premalignant lesions [7] [8]. Further on a host of clinical trials testing the
cancer preventive potential of retinoids in various tissues were conducted to determine the
best indications and modalities of retinoid use. These will be summarized in more detail in
this review.
1. Basic molecular biology of retinoids
Retinol, the precursor of retinoic acid (RA), is generally acquired as provitamin A in the
form of carotenoids, synthesized in leafy and yellow vegetables. Preformed vitamin A and
all-trans retinyl esters are found in liver, kidney and butter fat. Retinyl esters are hydrolyzed
in the intestinal lumen by retinyl ester hydrolases (REHs) to retinol. Other derivatives
dissolve in dietary lipids and are absorbed in the upper intestinal tract, although a direct
absorption pathway from bile also exists. The intestinal transcription factor ISX regulates
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critical steps of β-carotenoid uptake and retinol production [9]. Carotenoids are then
processed to retinaldehyde and converted to retinol. Retinol can be re-esterified with
palmitate or acetate by the lecithin-retinol acyltransferase (LRAT) enzyme in mucosal cells
and secreted in chylomicrons into the lymphatic system and the circulation [10]. The liver
captures retinoids from chylomicron remnants, where they undergo further conversion to
retinol and other bioactive forms. A minor fraction is distributed to peripheral tissues bound
to retinol binding proteins (RBPs) or albumin, but 90% of the stored vitamin A remains in
the liver [11]. At the target tissues the retinaldehyde dehydrogenase enzymes (RALDHs)
catalyze the rate-limiting step to local epithelial RA production (Figure 1) [12]. Through the
activation of retinoid signaling RALDH isoform 1 was recently shown to regulate cellular
respiration and adaptive thermogenesis in adipose tissue [13].
The lipophilic retinol can pass through the lipid bilayers of membranes, but the majority of
retinoids are taken up by target cells via the RBP4 receptor Stra6 [14]. Once reaching the
target tissues, retinol requires several enzymatic steps and proteins facilitating its transport
to exert its full range of biological activities (Figure 2). In fact, with respect to retinoid-
modulated transcription, cellular sensitivity to retinoic acid is primarily attributed to the
subnanomolar affinity of its intracellular binding proteins (CRABP II and FABP5),
delivering the ligand directly to its nuclear receptors. Retinol is reversibly transformed into
isomers such as 9-cis-retinoic acid (9-cis-RA), 13-cis-RA or all-trans-retinoic acid (atRA),
resulting in slightly different receptor binding properties and hence biological activities. In
the eye retinol is transformed into 11-cis retinaldehyde (11cRAL) and is responsible for
phototransduction through binding to the G-protein opsin. Other derivatives and chemically
distinct synthetic compounds activating the same signaling pathways are also termed
‘retinoids’, with some exhibiting greater activity than the most common atRA. It is
important to note, that the key steps responsible for setting physiologic retinol
concentrations are frequently altered in tumors and the changes associated with
carcinogenesis generally result in diminished retinoid signaling [15].
For the purpose of storage, upon entering the target tissues, retinal is esterified to a fatty
acid, providing the means of concentrating retinol within the cells [11]. The degradation of
retinoids in the body is also highly regulated and is catalyzed by cytochrome P-450
dependent enzymes in a hydroxylation and a subsequent oxidation step. Oxidized
metabolites of RA, primarily 4-oxo-RA, undergo conjugation with glucuronic acid and are
secreted with the bile.
In 1931 the Noble Prize in chemistry was awarded to Paul Karrer for determining the
structure of retinol, which he later successfully synthesized, and the compound soon became
commercially available. 9-cis-RA was the first compound shown to interact with RXRs [16]
and these ligand-bound RXR proteins were found to bind other nuclear hormone receptors
[17]. While RXR-binding compounds sharing some structural similarity with classic
retinoids are commonly referred to as ‘rexinoids’, chemically distinct molecules, like the
long-chain omega-3 fatty acid docosahexaenoic acid (DHA), were identified as endogenous
ligands of RXR and other nuclear receptors (i.e. PPARs) [18, 19].
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The list of endogenous and natural retinoids grew by the addition of synthetic derivatives
(Figure 3). First generation retinoids were nonaromatic molecules and included atRA
(Tretinone), 13-cis-RA (Isotretinoin) and 9-cis-RA (Alitretinoin). Second generation
compounds, such as etretinate and acitretin, were based on a monoaromatic structure and the
third generation agents, such as adapalene, tazorotene and bexarotene, are polyaromatic. The
number of synthetic retinoids developed to date is in the thousands.
Receptor-mediated retinoid signaling
The diversity of the functional effectors of vitamin A signaling is a function of the active
metabolites, their receptors and dimerization partners, potential co-regulators and response
element polymorphisms. The biological activity of natural retinoids is primarily mediated by
selective ligand-activated transcription factors of the nuclear hormone receptor family [20].
The receptors that bind naturally occurring classical retinoids, RARs have three isoforms, α
(NR1B1), β (NR1B2) and γ(NR1B3), as well as several splice variants arising from
alternative promoters. Another group of retinoid receptors, RXRs, whose ligands were
unknown at the time of their discovery, is also comprised of three isoforms. RXR-RAR
heterodimers act as ligand-dependent transcriptional regulators by binding to specific DNA-
response elements found in the promoter regions of target genes.
Phylogenically and structurally related, RARs and RXRs are both characterized by similar,
highly conserved modular domain structures. These contain C-terminal ligand binding
domains (LBDs) and central DNA-binding domains (DBDs) that include two zinc-finger
modules and two α-helices, as well as variable N-terminal regions. The N-terminal domain
that contains naturally disordered protein structures and whose role therefore has initially
been elusive, was implicated in a role of providing the flexibility needed for critical
posttranslational modification events by kinases and ubiquitin-ligases [21]. Nevertheless, the
functions of RARs are not limited to the regulation of cognate target genes. The assembly of
co-regulatory protein complexes is directed by the C-terminal ligand-binding domain of
RARs. In addition, RARs can act as co-repressors for other gene pathways.
RARs generally dimerize with an RXR as a partner to be activated by a ligand. This is an
unequal relationship, where RAR agonists can autonomously activate transcription, while a
full response to rexinoids requires binding of an RAR agonist. This is commonly referred to
as a ‘non-permissive’ nuclear receptor interaction. In contrast, RXR ligands are able to act
on their own through an RXR homodimer, or a variety of partners (PPARs, LXRs, THRs,
FXR, etc.). The latter partnering allows RXRs to activate transcription in the absence of a
rexinoid. Therefore these are called “permissive” heterodimers (Figure 4). Similar to most
type II nuclear receptors, retinoid receptors are retained in the nucleus regardless of their
ligand binding status. Bound to regulatory elements of their target genes as RXR/RAR
heterodimers, in the absence of ligands, they interact with the co-repressors NCoR, its
genetic paralog SMRT, Sin3 or others. These transcriptional repressor complexes, in turn,
recruit histone deacetylases that lead to the repression of target gene transcription [22].
Binding of an agonist triggers the repositioning of the H-12 C-terminal helix which results
in the dissociation of inhibitory co-regulators and recruitment of cofactor complexes such as
CBP/p300, SRCs or CARM1. Co-activators share a consensus α-helical LXXLL motif that
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fits into the hydrophobic cleft of the receptor LBD that modify local chromatin structure and
activate the basal transcription machinery.
While in normal tissues retinoid target genes are readily activated by an agonist, in tumors
epigenetic events often interfere with normal retinoid response. Critical elements of the
regulatory regions are methylated, which prevents the synthesis of gene specific messenger
RNA. A prime example is RARβ, in itself a retinoid-regulated gene, and a key regulator of
antineoplastic pathways induced by retinoids. The silencing of RARβ during epithelial
carcinogenesis is a prominent reason for retinoid resistance and limited efficacy of retinoid
action [23].
The majority of retinoids interact with the ligand binding domains of some or all of the
RARs, and some RAR-selective retinoids will bind RXRs, but with a very low affinity. The
significance of RXRs is more pronounced in their essential role for the efficient binding to
their genomic response elements of the subfamily 1 members of the nuclear hormone
receptor superfamily. The latter are generally considered potential RXR partners (Figure 4).
When forming dimers with RAR, RXRs are not able to respond to RXR-selective ligands,
unless RAR is liganded. This phenomenon is known as RXR subordination. Yet, RXRs are
not silent partners in RXR-RAR heterodimers, as simultaneous ligand binding of both
receptors results in synergistic transcriptional activation [24]. In contrast, some other
receptors (i.e. PPARs, LXRs, FXR) allow dimer activation by an RXR agonist, often
replicating the phenotypic response to their own ligands. Rexinoids may modulate gene
expression through biochemically detectable dimers of two RXRs; however activation of a
target gene as a result of RXR homodimer activation is difficult to show. Rexinoids exert
anti-proliferative, proapoptotic and differentiating biological effects on epithelial cells in
vitro, and have also been shown to inhibit cancer cell migration, invasiveness and
angiogenesis [25]. Naturally occurring ligands of RXRs include 9-cis-RA, docosahexaenoic
acid and phytanic acid, and the list extends over a line of synthetic agonists with improved
side-effect profiles or heterodimer-selective properties.
Retinoid receptor partners
The transcriptional outcome upon ligand activation is generally specific for the partner
receptor and results in the modulation of a transcriptional program commensurate with well-
defined biologic responses. For example, vitamin D receptor activation induces genes
responsible for maintaining calcium homeostasis and bone formation, LXR agonists activate
cholesterol transport mechanisms to protect cells from cholesterol overload, and FXR
regulates the enterohepatic circulation of bile acids. Recent in vitro data indicate that
retinoid signaling could also be mediated by other nuclear hormone receptors, such as
COUP-TF II (NR2F2) [26], RORβ (NR1F2) or TR2 [27], although the relevance of these
interactions in vivo remains to be shown.
Molecular mechanisms that modulate retinoid activity. The make-up of a nuclear receptor
dimer not only determines which genes it can regulate but also determines which of the
many co-regulatory molecules it may bind. The large number of possible complexes formed
by dimers and co-regulators lends a level of plasticity almost unparalleled by other
therapeutic targets. Furthermore, isotype-selective agonists may dictate differential
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responses by isotype-restricted co-repressor recruitment [28]. An additional mechanism to
modulate retinoid-dependent cell signaling pathways or diminish retinoid signaling has been
described in various cancer cells. Altered localization of RXRalpha was identified as a
mechanism that provides the means for rapid changes in hepatoma cell response to LPS, as
well as a survival strategy for breast cancer cells, which undergo apoptosis upon
nucleoplasmic overexpression of RXR [29, 30]. In hepatocellular carcinoma elevated ERK
activity phosphorylates RXRalpha on serine 260 and threonine 82, impairing its
ubiquitination and inhibiting transcription of its target genes by a dominant-negative
mechanism [31]. Phosphorylation events on RAR or co-repressors have also been reported
to restore transcriptional competence to RXR and promote differentiation in leukemia cells.
This raises the possibility of exploiting mechanisms that modulate heterodimer non-
permissivity as a therapeutic option [32].
The magnitude and duration of the hormone response is regulated by the ubiquitin-
dependent degradation of RARs and RXRs in the proteasome. In addition, retinoid receptors
integrate a series of signaling pathways by means of phosphorylation events which
cooperate with retinoids for the control of target gene expression. The highly conserved
ligand binding domain (LBD) contains several phosphorylation sites used by the kinases
PKA and MSK1, while the N-terminal domain contains a proline-rich motif that serves as
substrate for CDKs and MAPKs. The complexity in the transcriptional responses produced
by these multiple levels of regulation presents a unique therapeutic opportunity. Although
the induced molecular changes overlap, RXR selective agonists differ in their anti-tumor
effects from retinoids both in the preclinical and clinical settings.
Extra-nuclear retinoid signaling
In the classical sense, RA is a prototype of hormones that activate nuclear receptor
transcription factors that directly regulate gene expression. However, various studies from
the past decade demonstrated that several kinase cascades may be activated just minutes
after addition of retinol. As these events are transient, the possibility of a transcription-
dependent phenomenon can be ruled out. Numerous studies suggested that retinol
potentially exerts non-genomic activities through different types of interactions with
signaling kinases (Figure 5) [33]. For example, retinol can induce cytokine-dependent
activation of JAK2 and subsequently the STAT5 transcription factor, while being exchanged
from extracellular RBP to intracellular CRBP-I through Stra6 [34], creating a close link
between retinoid homeostasis and immune modulation. Stable association was shown
between the regulatory p85 subunit of PI3K and membrane-localized RARalpha in
neuroblastoma cells independent of the presence of RA, shifting to an RAR association with
the p110 catalytic subunit upon RA liganding [35]. PI3K activation then results in sequential
phosphorylation of downstream MAPKs and ribosomal S6 kinases, and is critical for RA-
dependent differentiation. Retinol may also induce differentiation in a receptor-independent
manner in bronchial epithelial cells by CREB-dependent transcriptional regulation. This
mechanism is mediated by protein kinase C through the activation of Erk1/2 and the p90 S6
kinase and is not dependent on retinoid receptors [36]. Extranuclear RARα localized to lipid
rafts was shown to trigger the phosphorylation of Rac1, p38 MAPKs and MSK1 through
activation of Gαq upon ligand binding (Figure 5) [37]. Activation of MSK1 phosphorylates
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RARs and ultimately triggers their recruitment to response elements of select target genes,
such as Cyp26A1 and RARbeta2 [38]. Nevertheless, RA-induced p38 activation has also
been associated with negative regulation of cell differentiation and growth inhibition [39]. In
neurons, RA was shown to play a role in neuritogenic differentiation through direct
interaction with cytoplasmic c-Src [40]. Cytosolic translocation of RXR has been reported in
hepatocytes, where it was implicated in the suppression of the inflammatory response to
LPS administration [29]. Another intriguing novel function of RAR was proposed by Chen
et al. in a study that localized RARalpha to the dendrites of neurons in association with
mRNA granules and revealed its involvement in the regulation of translation [41]. However,
many of these new mechanisms were identified in vitro and their relevance to human health
and pharmacology is not sufficiently understood yet.
2. Medical use of retinoids and rexinoids
Insufficient levels of vitamin A cause defects in vision, including night blindness, abnormal
formation of keratin in mucosal membranes and altered bone remodeling. Today, the classic
form of vitamin A deficiency due to malnutrition is rare. However, since it is an essential
nutrient, total vitamin A deprivation can ultimately result in death.
Retinoids have been used successfully for the treatment of skin disorders, in particular acne,
since the late 1940’s. In oncology, retinoids were first applied therapeutically and later as
preventive agents. However, with increasing understanding of their molecular action new
therapeutic indications were proposed. These include premalignant conditions, chronic
obstructive pulmonary disease and more recently Alzheimer’s and Parkinson’s disease. This
section will briefly summarize the current and proposed uses of retinoids and mechanistic
insight for their clinical utility, for oncologic and non-cancer related applications.
2.1. Retinoids in Dermatology
Commercially retinoids have made the greatest impact in the cosmetics arena, and they are
frequently used in creams and ointments to alleviate skin aging. Oral RA is efficacious in
keratinizing disorders, but is considered too toxic; therefore, the pharmaceutical industry
undertook the synthesis of retinoid derivatives to generate safer alternatives. Minor
structural changes, such as forming cis-isomers, resulted in a new class of oral retinoids with
strikingly different pharmacological properties. This was a milestone in dermatologic drug
discovery. For instance, the isomer 13-cis-retinoic acid demonstrated impressive efficacy in
acne and could cure severe acne conglobata [42]. In addition to systemic administration,
several retinoids are also available for topical use (Table 1).
The major skin diseases benefiting from retinoids include acne, prosiarsis, disorders of
keratinization, as well as precancerous lesions and non-melanoma skin cancer. For the
treatment of acne vulgaris retinoids represented a breakthrough in the 1980s. Isotretinoin,
the cis isomer of RA, normalizes epidermal differentiation, depresses sebum secretion and
reduces inflammation, making long-lasting remission possible. Psoriasis treatment often
involves immunosuppressive agents such as cyclosporine, tacrolimus and methotrexate and
biologic agents targeting T-cells or tumor necrosis factor-α. Therefore, retinoids play an
important role in cases where immunosuppression is not an acceptable side-effect, i.e. in
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children, patients at high risk of cancer or HIV carriers. Furthermore, the use of retinoids
allows a dose reduction of phototherapy with UVB or PUVA, when used in combination. In
plaque psoriasis acitretin and etretinate monotherapy may result in substantial improvement
in 50% of the cases. In erythrodermic and pustular psoriasis these retinoids represent first-
line therapy. Complete clearance requires the combination of retinoids with topical steroids,
vitamin D derivatives or phototherapy. Three retinoids are currently approved for systemic
therapy, isotretinoin (as Accutane, since 1982) for severe recalcitrant nodular acne,
etretinate (Tegison, 1986) for severe recalcitrant psoriasis and acitretin (Soriatane, 1996) for
severe psoriasis. Tretinoin tocoferil, the alpha-tocopherol ester of atRA, has been
successfully used to treat lichen and macular amyloidosis and skin ulcers [43] (see Table 1).
The prevention of cutaneous malignant diseases was among the first chemopreventive
applications of retinoids. Premalignant skin lesions, including actinic keratosis and HPV-
induced tumors are frequently treated with retinoids [44]. Patients at high-risk for skin
cancer because of genetic disposition (xeroderma pigmentosum), organ transplantation or
history of multiple tumors, may be treated with etretinate or acitretin for 6 months [45].
Chronic obstructive pulmonary disease (COPD) and emphysema
Endogeous retinoids play a critical role in the pre- and postnatal development of the lungs.
Indeed, the spatial and temporal distribution of retinaldehyde dehydrogenases, enzymes
responsible for local RA production define the regions and periods of embryonal lung
development [12]. Low retinol levels have been associated with bronchopulmonary
dysplasia, a chronic lung condition arising from premature birth. Lung hypoplasia has also
been associated with impaired cellular retinol uptake observed in clinical cases of Stra6
mutation [14]. Nevertheless, the importance of retinoid signaling extends to adult life and
healthy pulmonary function. An inverse relationship between serum retinol levels and lung
function was established in epidemiological studies conducted in smokers with COPD.
Therefore, it is an intriguing notion that retinoids might trigger alveolar regeneration in the
adult lung after tissue damage has occurred. In spite of the expectations, the Feasibility of
Retinoids for the Treatment of Emphysema (FORTE) study using atRA or 13-cis-RA in a 6-
month trial with a 3-month crossover period failed to detect significant improvements in CT
densitometry score, gas transfer or quality of life [46]. Preclinical models of dexamethasone-
impaired alveologenesis and airspace enlargement were used to identify the retinoid receptor
subtypes critical for mediating improvement in lung function. 13-cis-RA, retinol, or RXR
agonists did not, but 4-oxo RA and RARγ selective agents were able to induce regeneration
[47]. Thus, the safety and efficacy of palovarotene (R667), an oral γ-selective retinoid
agonist were tested in a randomized, double-blind, placebo-controlled study administering
drug for 1 year to 262 patients with emphysema or severe a(1)-antitrypsin deficiency (Table
1) [48]. While none of the differences reached statistical significance, most functional lung
parameters changed favorably in the retinoid-treated group versus the placebo group, and
pavarotene was generally well tolerated.
Neurologic diseases
There is a growing body of literature that suggests that pharmacological targeting of certain
nuclear receptors, particularly RXRs, LXRs and PPARs, is beneficial in neurodegenerative
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diseases [49, 50]. Genetic studies revealed that markers close to four of six retinoid receptor
genes and genes encoding three of the four known retinol-binding proteins had linkage to
Alzheimer’s disease (AD). More importantly, Cramer and coworkers showed that oral
administration of bexarotene in a mouse model of AD resulted in the clearance of soluble β-
amyloid (Abeta) in an apoE-dependent manner, and this was associated with a reversal of
cognitive, social, and olfactory deficits [51]. Some subsequent attempts to independently
reproduce the original report yielded controversial results, possibly due to the use of
different formulations of bexarotene. However, in a similar study PPARgamma and
RXRalpha agonists additively enhanced the microglial uptake of Abeta and improved spatial
memory [50]. A phase 1b and a phase 2 study are underway to examine the effect of
bexarotene on Abeta production and clearance.
In 2013 Parkinson’s disease was added to the list of conditions that could potentially benefit
from rexinoids. Screening for small molecules that interact with the orphan nuclear receptor
Nurr1 complexes, McFarland et al. showed that bexarotene can activate Nurr1, thereby
promoting growth and survival of dopaminergic neurons and preventing motor deficit [52].
While Nurr1 has no known natural agonists, by forming heterodimers with RXR, rexinoids
may indirectly modulate Nurr 1 action [53]. Interestingly, these effects were observed when
administering markedly lower than the typical clinical doses of bexarotene.
Successful clinical use of retinoids as cancer treatment
Retinoids were shown to promote differentiation and cell death of cancer cells in a number
of experimental systems [54, 55]. Some of the most successful therapeutic uses of retinoids
are due to their differentiation-inducing effects. The most relevant therapeutic trials and
applications of retinoids are summarized in Table 2.
Acute promyelocytic leukemia (APL): The best characterized example of retinoid receptor
malfunction in human disease is linked to acute promyelocyte leukemia (APL), in which
reciprocal chromosomal t(15,17) translocation between the genes of RARα and the
promyelocyte leukemia protein (PML) lead to the alteration of signaling through both
proteins. The resulting PML/RXRα fusion protein causes transcriptional repression and is
the single causative factor in the etiology of APL. Preclinical investigations revealed that
atRA induces terminal differentiation in the leukemic cells by promoting the degradation of
the fusion protein through the action of the UBE1L ubiquitin-activating enzyme [56]. Recent
studies identified the ubiquitin-specific protease UBP43, an antagonist of UBE1L, as an
antineoplastic target whose inhibition destabilizes the t(15;17) PML/RARα fusion protein
and induces apoptosis of APL cells [57]. The causative role of a single molecular defect
paved the way for differentiation-based therapy and led to successful clinical application of
atRA and 13-cis-RA for the treatment of APL (Table 2) [58]. Thus, the addition of atRA to
the standard, anthracycline-based therapy increases the odds of long-term survival to 80%,
compared to the chemotherapy alone which is curative in only 40% of the cases [58]. The 12
year follow-up of the 379 APL patients enrolled in the First North American Intergroup
Study has shown 80% complete responses (CR) in the patients randomized to atRA-
treatment for one year after chemotherapy, versus observation [59]. Notably, the
differentiating effect of atRA is synergistically enhanced by arsenic trioxide, a compound
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targeting the PML component of the oncoprotein [60], which achieves remission in the rare
cases of relapse after atRA and anthracycline therapy [61]. A recent phase III trial carried
out in low-intermediate risk APL patients demonstrated better two-year event-free (97% vs.
86%) and overall survival rates with the combination of atRA with arsenic trioxide than with
chemotherapy [62].
The use of retinoids in APL patients fundamentally changed the course of the disease for
most patients, and it is bound to transform our approach to cancer treatment in more than
one way. First, from a disease with a generally poor prognosis APL was transformed into the
most prognostically favorable subtype of acute myeloid leukemia. In addition, the
identification of this molecular defect led to the development of one of the first targeted
therapies and provided the rationale for personalized medicine. Moreover, the possibility of
achieving optimal efficacy without the use of chemotherapeutic drugs marks a novel path in
curative therapy that emphasizes improved standard of care.
Kaposi’s sarcoma: 9-cis-RA (alitretinoin) is successfully used in the treatment of refractory
cutaneous Kaposi’s sarcoma. Topical treatment with alitretinoin in a randomized, vehicle-
controlled phase III trial was associated with a 30% higher response rate with mild to
moderate adverse events over 12 weeks (Table 2) [63]. In AIDS-related Kaposi’s sarcoma
cases with increased IL-6 levels durable objective response to alitretinoin was reported with
improved rates and times to progression [64].
Squamous cell skin cancer: Following positive responses in the initial phase I/II studies with
13-cis-RA administered in combination with interferon-α2a, two out of three phase II/III
trials also demonstrated increased progression-free survival in advanced skin, cervical and
renal cancers [65]. A phase III randomized trial did not confirm the results, as no prevention
of tumor recurrence or second primary tumors were detected, possibly due to a lack of
appropriate statistical power [66]. Nonrandomized trials of 13-cis-RA in combination with
interferon-α2a and chemotherapy for the treatment of advanced head and neck cancers
showed promising results, and are awaiting confirmation by randomized studies [67].
Cutaneous T-cell lymphoma (CTCL): Natural and synthetic analogs of RA have been used
for years both as monotherapy and in combinations for the treatment of CTCL [45]. The
RXR-selective retinoid bexarotene was found to be active against all stages of the disease.
Bexarotene showed a 45–54% response rate in a small phase 2 trial [68] and a 60% response
rate in a retrospective study of long-term CTCL patients, earning FDA approval for the
treatment of CTCL refractory to at least one previous therapy [68, 69].
Neuroblastoma: More than a decade ago it was suggested that retinoids may be beneficial in
the treatment of neuroblastoma [70]. The greatest challenge in the treatment of
neuroblastomas is its high recurrence rate. Recently a randomized phase III study
established that intermittent dosing of 13-cis-RA significantly improved survival (Table 2)
[71]. A phase I trial of fenretinide delivered in an oral powderized lipid complex (LXS) was
reported to have anti-tumor activity in patients with refractory neuroblastoma, reaching
higher plasma levels yet reduced toxicity as compared to conventional pills [72].
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Breast cancer: In the only single agent clinical trial with atRA, this agent failed to achieve
the primary response endpoint in patients with metastatic breast cancer [73]. Thus,
subsequent studies investigated retinoid efficacy in combination with tamoxifen or
interferons [74]. Isotretinoin, alitretinoin and retinyl palmitate were also tested as therapies
in late-stage post-menopausal breast cancer patients (Table 2). No potentiation in the effect
of tamoxifen or a difference in survival was detected [75], although a clinical response was
seen in 55% of the patients treated with retinyl palmitate [76]. Clinical benefit with
bexarotene was documented in 20% of patients with hormone-refractory metastatic breast
cancers, with lower toxicity than seen with retinoids [77].
Lung cancer: Preclinical findings of anti-proliferative and pro-apoptotic activity in
squamous cell cancers inspired a randomized phase II trial in advanced non-small cell lung
cancer (NSCLC). The addition of atRA to chemotherapy yielded a benefit of increased
response rates and progression-free survival [78]. Furthermore, a phase I/II first-line
metastatic study of bexarotene combined with vinorelbine and cisplatin demonstrated a
marked extension in median survival [79]. Unfortunately, these results were not confirmed
in subsequent phase III trials of bexarotene plus cisplatin and vinorelbine, as progression-
free or overall survival of NSCLC patients receiving combined treatment including
bexarotene was indistinguishable from the placebo group [80] (Table 2). The Biomarker-
integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial
marked a paradigm shift in the design of clinical studies by achieving personalized therapy
through adaptive randomization of patients [81]. With one of the four treatment arms
incorporating bexarotene in combination with the tyrosine kinase inhibitor erlotinib, the
BATTLE trial also revealed further detail on the applicability of bexarotene in lung cancer.
Erlotinib plus bexarotene produced a 50% overall 8-week disease control rate (DCR) in
pretreated lung cancer patients, and were particularly effective in the groups positive for
EGFR mutations and RXRα/cyclinD1 protein expression.
Related clinical results were obtained and reported in a phase II trial conducted in
chemotherapy-refractory KRAS mutation-positive NSCLCs [82]. But in addition to showing
major clinical responses induced by the combination of bexarotene and erlotinib in advanced
NSCLC, these studies defined cyclin D1 as a predictive biomarker, which enables
oncologists to make personalized therapy decisions [83]. Cyclin D1, frequently
overexpressed in lung cancer, plays a significant role in premalignant lung carcinogenesis,
and is therefore a relevant target. Retinoid receptor selective agonists in human bronchial
epithelial cells induced cyclin D1 degradation through RARbeta and RXR-dependent
ubiquitination [84]. It has been proposed that dual targeting of cyclin D1 will result in
increased efficacy, and overcome limitations of retinoid treatment in patients carrying
polymorphisms in the cyclin D1 gene that make cyclin D1 resistant to degradation.
Challenges in the Medical Use of Retinoids
Pharmacodynamic considerations: Retinoid bioavailability is a crucial factor for the
prediction of retinoid effectiveness and toxicity, particularly in light of the multiple
enzymatic steps involved in both the creation and the degradation of active metabolites.
Retinoid pharmacokinetics is further complicated by the differential lipid solubility of these
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agents. For example, etretinate is 50 times more lipophilic than acitretin and is released
slowly from adipose tissues, where it is stored [85]. Thus, etretinate levels are detectable in
serum for 2–3 years, while acitretin, isotretinoin and its metabolites reach normal levels two
weeks after discontinuation of treatment. In vivo, pharmacodynamic mechanisms exert
marked pharmacokinetic effects on locally available, intratumoral drug levels and have been
shown to be a major determinant of the biological response to treatment [83].
Retinoid toxicity: Systemic retinoid toxicity in adults is similar to hypervitaminosis A,
manifested in skin dryness, conjunctivitis and hair loss. The cutaneous and metabolic side-
effects of retinoid treatment are dose-dependent and reversible. A minor fraction of APL
patients receiving atRA (14–16%) develop retinoic acid syndrome (RAS), encompassing
dyspnea, fever, pulmonary hemorrhage and respiratory failure. While these potentially lethal
complications can be successfully treated by high-dose steroids, identifying patients who
will develop RAS is critical. High initial and increasing white blood cell counts and CD13
expression on leukemic cells indicate predisposition to RAS [86].
Yet, in general, retinoids belong to the group of often well-tolerated pharmacologic agents.
Many patients have been treated with retinoids, particularly etretinate or isotretinoin,
continuously for as many as 15 years without developing signs of chronic toxicity [87].
However, because retinoids play an important role in the differentiation of embryonic tissue
and organ formation, exposure of the fetus to therapeutic doses of retinoids is associated
with teratogenic side effects. Thus, systemic use of these agents in patients of child-bearing
age requires contraception for the duration of sustained retinoid levels in the body.
In contrast to retinoids, RXR-selective ligands have reduced teratogenicity and cutaneous
toxicity. The most frequent adverse effects associated with rexinoid use are hyperlipidemia
including triglycerides and cholesterol, the suppression of thyroid function and osteoporosis.
Hyperlipidemia is treated with dose adjustment and lipid lowering drugs [88]. Individuals
requiring life-long treatment should be subject to close monitoring. In comparison, long-
term treatment with rexinoids is associated with a lower level of adverse effects than
retinoids.
Retinoid resistance: Malignant transformation of epithelial cells may profoundly change
retinol metabolism and contribute to the development of retinoid resistance [15]. Cellular
retinoid uptake is regulated by LRAT, the enzyme that esterifies retinol to retinyl esters, and
the RBP receptor Stra6. LRAT expression is suppressed in many human tissues undergoing
malignant transformation, including breast, prostate, skin, kidney or bladder, resulting in
low intracellular retinyl ester levels [89]. Stra6 mutations are associated with developmental
errors [90]. Breast and prostate cancers also express aberrantly low levels of ALDH1a2, the
enzyme forming RA from retinaldehyde [91]. ALDH1a2 has therefore been proposed as a
tumor suppressor [92]. Mechanisms of retinoid clearance may also be affected in cancer
cells, mainly through the over-expression of CYP26A1, the enzyme that oxidizes RA to
more polar metabolites [93].
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3. The use of retinoids for cancer prevention
The original concept of cancer prevention using specific compounds traces back to the early
20th century when Wolbach first reported on his rat study with “tissue changes following
deprivation of fat-soluble A vitamin” and the reverse changes that follow, when the rats are
restored to an adequate vitamin A diet [94]. Epidemiological data indicate that vitamin A
deficiency is associated with higher susceptibility to chemical carcinogens [95, 96]. Few
preclinical studies are designed to determine which stage of carcinogenesis is most
effectively inhibited by retinoids [97]; yet this question needs to be elucidated. On the
molecular level, the potential of retinoids to prevent cancers is based on the notion that
specific early molecular alterations required for cancer progression, but not essential in later
stages of tumorigenicity, may be effectively targeted by pharmacologic interventions.
Accordingly, in experimental models retinoids appear more successful in blocking pre-
neoplastic transformation or early phase neoplasia than reversing cancer. Although vitamin
A derivatives have proved to be curative or useful as adjuvants in select overt cancers in
humans, clinically applied retinoids are most effective in the treatment of precancerous
lesions, such as leukoplakias, cervical dysplasia, and actinic keratosis [98] [44, 99].
Decreased proliferation is considered one of the best biomarkers of a cancer preventive
effect. Many transcriptional target genes of retinoids help explain this correlation, as several
inhibitors of cell cycle progression are direct targets of retinoids. The upregulation of
RARβ2 by atRA and acyclic retinoids is a key factor in the inhibitory effect of RA on cell
proliferation [100], as it induces the expression of p21CIP1 and p27Kip1, and inhibits the
proteasome-dependent proteolysis of p27Kip1. Furthermore, RA stimulates the ubiquitin-
mediated degradation of cyclin D1, thereby suppressing cyclin-dependent kinase (CDK)
activities, interfering with retinoblastoma (Rb) phosphorylation and cyclin E expression
which ultimately leads to the transition of cells into S-phase [101, 102]. Retinoids exhibit an
ability to move cells towards more differentiated states [103]. However, in many cases these
changes do not account for the net suppression of tumor formation in various tissues treated
with retinoids. Retinoids and especially rexinoids have a major impact on cellular
metabolism, harnessing the opportunity to differentially affect transformed versus normal
epithelial cells [104–106]. Retinoids effectively modulate inflammatory pathways critical
for carcinogenesis, which thus may offer viable targets for chemoprevention [107–109].
Furthermore, increasing evidence points to the reprogramming of stromal cells, fibroblasts,
adipocytes, and immune cells by retinoids as potentially important factors in modulating
tumorigenesis in a number of tissues [110, 111]. Some of the new approaches to retinoid-
induced preventive activity may target the stromal environment or be based on
immunomodulatory effects.
Preclinical investigations on the cancer preventive potential of retinoids. Although little
epidemiologic data exist regarding the potential of vitamin A or carotenoids to reduce breast
cancer risk, a wealth of in vitro studies have indicated which cellular pathways result in anti-
proliferative and pro-differentiation mechanisms in the breast, as well as in other organs
[112] [113].
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The ability of retinoids to prevent cancer has been demonstrated in a number of animal
models. Retinyl acetate and the synthetic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR)
have been used to prevent mammary carcinogenesis in rats exposed to chemical carcinogens
[114]. The naturally occurring 9-cis-RA was also found to suppress mammary tumors alone
or in combination with low-dose tamoxifen [115, 116]. To avert the toxicity associated with
9-cis-RA, synthetic RXR-selective analogues such as bexarotene (Targretin, LGD1069) and
LGD100268 were designed and tested. Both bexarotene and LGD100268 have proved
superior to 9-cis-RA in preventing estrogen receptor (ER)-negative breast cancer in
transgenic mice [117], either as single agents, or in combination with anti-estrogens [118,
119]. Potent chemopreventive efficacy of bexarotene was also demonstrated in combination
with COX-2 inhibitors [120]. Interestingly, not only celecoxib, but bexarotene as well was
found to reduce aromatase activity in the breast. Estrogen is a major driver in many breast
cancers and stimulates cell proliferation, while RA has growth inhibitory effects in most
cells. Hua et al. showed that RAR and estrogen receptor (ER)-α regulate their target genes in
an antagonistic manner, with ER-α upregulating and RAR inhibiting proliferation and
survival. This genomic antagonism between estrogen and retinoid signaling was
demonstrated in a comprehensive study of genomic nuclear receptor binding and gene
expression, which revealed a 39% overlap in genomic regions potentially binding both ER-α
and RARs [121]. Understanding the crosstalk mechanisms between estrogen and retinoid
signaling may open new opportunities for cancer preventive interventions.
Intestinal polyp formation in mice mutated in the adenomatous polyposis coli (APC) gene,
Apc (Min/+) mice, was suppressed by dietary administration of bexarotene by up to 60% in
male and 37% in female mice [122]. Intestinal tumors arising in spite of bexarotene dosing
showed decreased proliferation markers and inflammatory cytokines. Chemoprevention
studies in C57BL/6J-Apc(Min/+) mice demonstrated that suppression of tumor growth and
prolonged survival could also be achieved by short-term and intermittent treatment by
retinyl acetate and TRAIL (TNF-related apoptosis inducing ligand), due to apoptosis
induced specifically in intestinal polyps [123].
Rexinoids were effective in A/J mouse models of lung carcinogenesis induced by K-ras or
p53 dominant negative mutations, in monotherapy or in combination with triterpenoids [124,
125]. In both cases cancer preventive activities were associated with reduced cell
proliferation and decreased expression of tumor growth-related biomarkers, i.e. cyclins D1
and E. Although preclinical data have suggested a potential role for retinoids against
prostate cancer formation, these outcomes in animals have not translated into clinical
efficacy [92] [126].
The successes and failures of the available retinoids have sparked further research to
develop better anticancer agents with improved efficacy and side-effect profiles. Acyclic
retinoids were found to be effective specifically for the prevention of hepatocellular
carcinomas [127]. Long-term administration of acyclic retinoids significantly inhibited
hepatic adenomas through inhibition of Ras and phosphorylation of ERK, and increased
expression of RARβ and p21 [128]. The synthetic rexinoid analog, 9-cis UAB30 has been
tested as a breast cancer prevention agent. It exhibits similar pharmacokinetic parameters to
9-cis-RA, but lacks the lipid inducing propensity of other RXR agonists [129].
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Clinical investigations on the cancer preventive potential of retinoids: One of the first
reports on molecular-targeted chemoprevention research demonstrated that an adjuvant high
dose of isotretinoin (13-cis-RA) prevented second primary tumors in patients with curatively
treated head and neck cancer [6]. Preclinical and epidemiologic data soon inspired clinical
testing of the cancer preventive effects of retinoids in various target tissues.
Several retinoids have shown benefit in the prevention of skin cancers (Table 3). A sustained
cancer preventive effect was demonstrated in patients with basal cell nevus syndrome
treated with tazarotene, a topical retinoid, even 5 months after topical treatment was
stopped; in addition, preexisting microscopic basal cell carcinomas were inhibited [168].
Furthermore, isotretinoin was shown to reverse suppression of RARβ in premalignant oral
lesions [24]. Clinical efficacy in recurring and retinoid-resistant leukoplakia was achieved at
a low dose of fenretinide [98, 130].
Clinical trials using isotretinoin to prevent recurrence or second primary head and neck
squamous cell carcinomas (HNSCC) have yielded mixed results. In the initial phase II study
isotretinoin treatment was associated with a significant reduction in second primary head
and neck cancers or recurrence [6]. However, in a phase III study using a larger cohort
(enrollment 1190) no significant delay in incidence of second primary cancers or recurrence
with isotretinoin treatment was confimed [131, 132]. In order to facilitate prediction of
favorable responses to isotretinoin as a cancer preventive agent, genetic polymorphisms in
critical cancer signaling pathways were interrogated. Inclusion of several of these genetic
loci improved the discriminatory ability of the risk/response prediction model to almost 80%
as compared to approximately 66% for a model based solely on clinical and epidemiologic
characteristics, suggesting the use of genetic markers as a promising route to identify the
best responders to isotretinoin treatment [133].
Fenretinide (N-(4-hydroxyphenyl)retinamide, 4-HPR) was proposed for the treatment and
chemoprevention of retinoblastoma based on preclinical studies, since it was shown to
induce cell death in neuroectodermal tumors through oxidative stress and tumor cell
ceramide levels [70]. Fenretinide also inhibited tumor growth in a xenograft model of Y79
neuroblastoma cells by inhibiting angiogenesis, making it potentially useful as an agent for
early clinical intervention [134]. Clinical trials evaluating the combination of retinoids with
ceramide modulators or anti-disialoganglioside antibodies were proposed for the treatment
of high-risk neuroblastoma [135].
Epidemiologic data on vitamin A and β-carotene provided the primary rationale for the
largest lung cancer prevention trials, because preclinical in vivo data supporting these agents
were limited. A window-of-opportunity presurgical trial in non-small cell lung cancer
demonstrated that critical biomarkers, including cyclin D1, Ki67 and phosphorylated EGFR
were favorably modulated by bexarotene [83]. Treatment of former smokers for 3 months
with 9-cis-RA led to a significant increase in RAR-β expression in the bronchial epithelium
as compared with placebo [136]. However, in spite of promising prior biomarker data, the
clinical trials of RAR agonists for lung cancer prevention were largely unsuccessful.
Overall, beta-carotene proved ineffective in both the Alpha-Tocopherol, Beta-Carotene
Cancer Prevention (ATBC) and the Carotene and Retinol Efficacy Trial (CARET).
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However, in former smokers beta-carotene slightly decreased lung cancer incidence (RR
~0.8), while increasing the chance of developing tumors in active smokers. In contrast to
RAR agonists, bexarotene showed marked disease stabilization in the follow-up of the initial
phase I trial in heavily pre-treated patients with advanced lung cancer [113]. A phase III
study comparing the effectiveness of chemotherapy with or without bexarotene in the
treatment of NSCLC found that the development of high-grade hypertriglyceridemia
correlated with improved survival [137]. However, in unstratified patient populations, the
addition of bexarotene to first-line treatment of NSCLC failed to show a benefit over
standard chemotherapy [80]. These and many preclinical observations suggest a possible
functional correlation between lipogenic activity and tumorigenesis, which remains to be
assessed. Several groups have put forward the idea of inhalation as a more effective means
of retinoid delivery with potentially reduced side effects. A pilot study showed that inhaled
mid-dose 13-cis-RA upregulated the expression of all RARs and reduced carcinogen-
induced tumor multiplicity by 67–88% [138]. In a small cell lung cancer (SCLC) model of
lung-specific Rb1/p53 knock-out mice the combination of bexarotene with budesonide was
shown to suppress tumor incidence and load [139]. Administration of aerosolized
bexarotene in a rodent model not only inhibited lung tumorigenesis, but did so without
elevating serum cholesterol or triglyceride levels [140].
Several lines of preclinical evidence suggested that retinoids and rexinoids have strong
potential to inhibit breast cancer formation in both ER-positive and ER-negative mouse
models [117, 118]. Repeated serum measurements of carotenoids and tocopherols over a
period of six years identified an inverse correlation with breast cancer risk in
postmenopausal women [141]. Due to the minimal efficacy of first generation retinoids
documented in the treatment trials, and because fenretinide selectively accumulates in
mammary tissue, chemoprevention studies for breast cancer focused on fenretinide [142].
The first large randomized studies showed the ability of fenretinide to reduce the incidence
of second breast cancers in premenopausal women (Table 3) [143]. Strikingly, the protective
effect continued to be manifest for up to 10 years after cessation of the treatment. In addition
to breast cancer, fenretinide also reduced the incidence of ovarian cancers in BRCA1 and 2
mutation carriers [144]. Bexarotene was tested in women at high risk of breast cancer in a
multicenter biomarker trial for breast chemoprevention. While overall significant changes in
proliferative and apoptotic markers could not be shown, cyclin D1 was suppressed by
bexarotene in mammary biopsy tissues from pre-menopausal subjects [145].
Acyclic retinoids (ACRs) are a unique class of retinoids developed specifically for the
purpose of chemoprevention, and successfully tested in hepatocellular carcinoma (HCC)
patients for their ability to prevent second primary tumors. A double-blind, placebo-
controlled clinical trial conducted in Japan using peretinoin following chemotherapy
demonstrated significantly reduced recurrence in HCC patients [146]. Administration of
ACR over one year improved recurrence-free survival, as well as overall survival after a
follow-up of over 3 years [147]. Based on the results of a phase I pharmacokinetic study
300–600 mg/day were considered safe and used in a subsequent phase II/III randomized,
double-blind, placebo-controlled study of peretinoin in patients with hepatitis C-related
HCC, to determine benefits in recurrence-free survival (RFS) as a primary outcome [148].
Although the primary comparison with placebo was not significant (p=0.434), improved
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survival was assumed in patients with stable liver function and treated with the higher dose
peretinoin [149]. The hazard ratios for RFS in the high dose vs. placebo group were
markedly low (0.27) two years after randomization.
Strategies to minimize retinoid toxicity
Beneath the wealth of pharmacological benefits, toxicity represents the main limitation to
the chronic use of retinoids. Therefore, it is imperative to work out viable strategies to
minimize toxicity without compromising therapeutic effectiveness. One successful approach
includes administering high, intermittent doses of a retinoid, which may be more effective
than continuous low-dose therapy, as exemplified by 13-cis-RA to improve event-free
survival of neuroblastoma patients [150]. Muindi et al. determined in pharmacokinetic
measurements of the FORTE study that intermittent therapy with high-dose atRA would
result in the greatest atRA exposure [151]. Other efforts to minimize retinoid-related adverse
effects encompass modifications to the basic retinoid structure. For example, the alpha-
tocopheryl ester of atRA, tretinoin tocoferil, is 150 times less toxic than the parent
compound and lacks teratogenicity [152]. A synthetic analogue of 9-cis-retinoic acid,
9cUAB30, primarily binds RXR, yet lacks the hypertriglyceridemic effect of most rexinoids
[153]. The first pharmacokinetic studies aim to determine the optimal dose and side-effects
of this drug [154]. However, new drug development based on structure-function relationship
is expensive and very time-consuming.
Alternatively, the use of combinations harbors great potential with respect to both increasing
efficacy, as well as limiting toxicity. Combinations synergistic for the cancer preventive
effect or its surrogate are expected to retain efficacy even at low doses of the agents, where
drug-specific side-effects are reduced. Synergistic interactions may result from affecting the
same or related pathways, or may involve unrelated pathways.
A unique mechanism of cooperation (or synergy) was shown between vitamin K2 and both
acyclic retinoids or 9-cis-RA, offering a perspective for a potential chemopreventive
combination. It was proposed that vitamin K2 prevents the phosphorylation and
accumulation of inactive RXRα by inhibiting Ras and extracellular signal-regulated kinase
activation, allowing retinoids to exert their cancer preventive effect in hepatic cells [155].
ACRs themselves may be able to restore impaired receptor function through inhibition of
RXR phosphorylation. Another approach is to examine potential enhancing interactions
among the multitude of partnering nuclear hormone receptors. This way anti-proliferative
and anti-tumor cooperation was demonstrated between RXRs and PPARs in premalignant
mammary epithelial cells, as well as in vivo [156, 157].
Targeting the same pathways by two agents may accentuate an overlapping spectrum of
adverse effects. Therefore, current preclinical studies take an unbiased approach to identify
synergistic combinations in vitro in phenotypic compound screens of premalignant precursor
cells or more recently using computational methods. Such combinations might consist of a
component that exhibits proven cancer preventive characteristics and a second agent
selected from a pool of compounds based on its ability to enhance the effect of the primary
chemopreventive agent. Candidate combinations are subsequently tested in mechanistic
studies and animal models, with a goal of being translated into clinical settings. The
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inclusion of agents that are already FDA-approved and clinically tested, albeit with a
different scope of indications, will require “drug repurposing”, but might be the fastest, and
most efficient ways to arrive at clinically testable, low-toxicity alternatives for cancer
prevention [158]. One novel prospect for a breast cancer preventive combination includes
the rexinoid bexarotene and a non-selective beta-adrenergic inhibitor, carvedilol. Identified
in high-throughput compound screens of premalignant breast epithelial cells for
combinations synergistically anti-proliferative over a wide dose-range, low doses of these
two agents are being tested in transgenic mouse models of breast cancer to establish their
preventive capacity (I.U. unpublished observation). Beyond the immediate clinical
applicability of the two FDA-approved agents, this and similar investigations will likely
reveal potentially exploitable novel interactions of adrenergic signaling pathways and
rexinoid-dependent anti-cancer activity.
Summary - The future of retinoids in the prevention of cancer
The medical use of retinoids extends over more than half a century and marks some of the
successes in pharmacology. Topical treatments are valuable in conditions associated with
differentiation defects and the application of Tazarotene was decisive for the curative
outcome of APL therapy. However, apart from leukemias, skin cancers and neuroblastoma,
among other examples, currently retinoids play a more limited role in cancer treatment and
prevention than would be expected based on their favorable pharmacologic properties.
Retinoids and rexinoids are ligands recognized by specific receptors which directly interact
with the genome and regulate concerted programs of gene expression. These programs elicit
coordinated physiologic changes that can antagonize malignant transformation, promote
differentiation, cause apoptosis, insulin sensitivity, oxidative metabolism, and immune
modulation, or suppress inflammation. The large number of possible complexes of nuclear
receptor dimers and co-regulators formed in response to ligand binding confers tissue-
selective modulation of cell function that collectively exert antineoplastic effects.
Although both retinoids and rexinoids possess a spectrum of pleiotropic effects, it is unlikely
that retinoid monotherapy will be a preventive strategy for most cancers. However, as
multifunctional agents, retinoids are especially well-suited to combination therapies [159].
From a long line of studies it appears that to best exploit the potential of retinoid
pharmacology optimal combinations with other agents will have to be identified and the
issues of resistance and toxicity addressed systematically in preclinical models and relevant
clinical trials. There is a need to identify validated biomarkers in order to predict retinoid
response in the target tissue as clinical data demonstrate that retinoid action is often
dependent on specific cellular contexts and epigenetic modifications. Such biomarkers may
be derived from preclinical studies or from patient material from window-of-opportunity
trials. To take advantage of the full potential of retinoids such biomarkers will have to be
used to better define clinically-responsive populations.
Useful knowledge can be gained from retrospective studies asking pharmacogenomic
questions, by linking specific genetic loci or single nucleotide polymorphims to therapeutic
efficacy [133]. Ample preclinical and ex vivo data are available about the downstream
transcriptional responses of target organs that should allow the monitoring of the target-
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specific activity after retinoid treatment. These changes in the expression of retinoid target
genes would also be important for bioavailability assessment.
From the prevention aspect of clinical use, rexinoids seem to outweigh retinoid agonists in
their activities. While exhibiting modest activity against existing tumors (with the exception
of CTCL), rexinoids are far more effective preventive agents than are retinoids in preclinical
models. Furthermore, long-term treatment with rexinoids is associated with significantly
fewer adverse effects than retinoids. Therefore, rexinoids should be clinically tested for their
ability to suppress tumor formation in organ sites where preclinical and biomarker studies
have demonstrated efficacy. Future hypothesis-driven clinical trials are needed to take full
advantage in the clinic of the promise of retinoid and rexinoid pharmacology.
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Figure 1. Pathways of retinoid metabolism and distribution throughout the body
Vitamin A, derived from β-carotene, or as a provitamin from animal sources, is processed to
retinol and either stored as retinyl esters or distributed to the peripheral tissues via retinol
binding proteins. Target tissues create and use various isomers for specific signaling
purposes.
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Figure 2. Molecular mechanisms of retinoid and rexinoid action in the target cell
To be active, vitamin A requires multiple enzymatic steps and transport. Cellular retinol
(ADH4) and retinaldehyde (RALDH) dehydrogenases oxidize retinol to retinaldehyde and
further to all-trans-retinoic acid (atRA). High affinity binding to CRABP II delivers the
ligands to activate transcription through their nuclear receptors. Following activation, atRA
is degraded by the CYP26A1 system, while RAR is degraded in the proteasome or
inactivated by phosphorylation.
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Figure 3. Synthetic retinoids and rexinoids tested or used for cancer prevention
The structure of synthetic retinoids used in preclinical and clinical cancer prevention studies
are shown.
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Figure 4. Nuclear Hormone Receptor Partners of RXR with or without known ligands
RXR partners with RAR to form the dimeric retinoid receptor, and also with many other
partners that bind ligands (Vitamin D receptor, PPAR receptor, thyroid hormone receptor
(TR), and other partners shown on the left side of this figure). RXR also binds partners that
have no known ligand designated “orphan receptors” (such as COUP-TF I and II, NGF1B,
and nurr 1 and others shown on the right side of the figure).
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Figure 5. Extranuclear and non-transcriptional effects of retinoic acid (RA)
Pathways involving extranuclear biological activity of RA may result in various outcomes.
1. Cytokine-dependent retinol uptake via Stra6 Involves STAT5 activation and immune
regulation. 2. Differentiation through CREB-dependent induction of retinoid target genes
was reported to be triggered by receptor-independent activation of protein kinase C (PKC),
the Erk1/2 MAPK (ERK) and the p90S6 kinase (RSK) by RA, or the interaction of
membrane-associated PI3K and RAR-alpha. Lipid raft-bound RAR-alpha activating Gαq
upon agonist stimulation leads to phosphorylation and nuclear translocation of p38MAPKs,
activating MSK1 and inducing differentiation. 3. Activation of p38 by RA may also inhibit
cell differentiation via downstream MAPKAPK2 activation, 4. Neuronal differentiation
through the direct interaction of cytosolic RAR-gamma with Src.
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